WO1993006911A1 - Method of treating blood - Google Patents

Method of treating blood Download PDF

Info

Publication number
WO1993006911A1
WO1993006911A1 PCT/US1992/008060 US9208060W WO9306911A1 WO 1993006911 A1 WO1993006911 A1 WO 1993006911A1 US 9208060 W US9208060 W US 9208060W WO 9306911 A1 WO9306911 A1 WO 9306911A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
iodine
cross
filter
linked pvp
Prior art date
Application number
PCT/US1992/008060
Other languages
French (fr)
Inventor
Edward Shanbrom
Herbert Lieberman
John J. Merianos
Original Assignee
Isp Investments Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isp Investments Inc. filed Critical Isp Investments Inc.
Publication of WO1993006911A1 publication Critical patent/WO1993006911A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances

Definitions

  • a method for treating blood compositions to inactivate pathogenic microorganisms therein comprises contacting cross-linked polyvinylpyrrolidone-iodine with blood, separating the cross-linked PVP-iodine and the cells therein from the soluble portion of the blood, and removing any residual iodine from the thus-treated soluble portion of the blood.
  • the preferred method comprises:
  • the cross-linked PVP-iodine has a particle size of about 40-150 microns.
  • the active agent for removing pathogenic microorganisms present in blood is the cross-linked complex of polyvinylpyrrolidone and iodine.
  • This complex is formed as the reaction product of cross-linked polyvinyl ⁇ pyrrolidone, which is available from International Specialty Products (ISP) , and molecular iodine.
  • ISP International Specialty Products
  • the cross-linked PVP-iodine is available from ISP as a stable, free-flowing powder which is water-insoluble.
  • the preferred cross-linked PVP-iodine product can be characterized as having about 10% available iodine and about 5% iodide in the complex.
  • a filter having a porosity equivalent to a 325 mesh screen, i.e. a porosity of 44 microns, was loaded with cross-linked PVP-iodine powder prepared according to the method of the aforementioned U.S. Patent Application, and having a particle size greater than 44 microns, to a bed depth of about 3 inches. Then a blood composition, with any microorganisms therein, was passed through the thus-loaded filter for a contact time of about 2 minutes. The filtrate thus-obtained showed less than 25 ppm of iodine therein. This treatment is effective in killing any microorganisms, including viruses, present in the blood sample.
  • the blood cells of the treated blood remained on the filter bed; these blood cells and the cross-linked PVP-iodine are washed with isotonic solution, and transferred to a second filter having a porosity greater than the particle size of the cross-linked PVP-iodine but smaller than the red and white blood cells.
  • washing with isotonic solution will separate the cross-linked PVP-iodine from the treated red and white blood cells.
  • the filtrate which has dead bacterial cells and dead viruses included therein is subjected to a second filtration to remove the dead bacterial cells present therein.
  • the treated soluble portion of the blood is purified by contacting it with cross-linked PVP to remove any residual iodine therein.
  • soluble blood is obtained which is substantially free of pathogenic microorganisms and residual iodine.
  • a preferred method for accomplishing this is to provide a purification filter loaded with cross-linked PVP, and passing the treated soluble portion of the blood through the loaded filter whereupon the PVP will complex with residual iodine therein on the filter, while the purified, treated soluble portion of the blood passes through.

Abstract

A method is provided for treating blood and its compositions to remove pathogenic microorganisms present therein. The invention comprises contacting cross-linked polyvinylpyrrolidone-iodine (PVP-I2) with blood and separating the cross-linked PVP-iodine and the cells therein from the soluble portion of the blood. The preferred method involves loading cross-linked polyvinylpyrrolidone-iodine onto a filter having a porosity less than either the particle size of the cross-linked PVP-iodine or the blood cells in the composition, contacting the thus-loaded filter bed with the blood thereby to inactivate the microorganisms therein, passing the treated soluble portion of the blood composition through said filter, collecting the thus-treated blood cells remaining on the filter, and purifying the treated soluble portion of the blood composition by contacting it with cross-linked PVP to remove any residual iodine therein.

Description

METHOD OF TREATING BLOOD
A method is provided herein for treating blood compositions to inactivate pathogenic microorganisms therein. The invention comprises contacting cross-linked polyvinylpyrrolidone-iodine with blood, separating the cross-linked PVP-iodine and the cells therein from the soluble portion of the blood, and removing any residual iodine from the thus-treated soluble portion of the blood.
The preferred method comprises:
(a) loading cross-linked PVP-iodine onto a filter having a porosity less than the particle sizes of both said cross-linked PVP-iodine and the red and white cells in the blood,
(b) contacting the loaded filter with said blood for a period of time sufficient to enable said cross-linked PVP-iodine thereon to inactivate or destroy any pathogenic microorganisms present in the blood,
(c) passing the soluble portion of the blood through said filter, and collecting the blood cells remaining on the filter, and
(d) contacting the treated soluble portion of the blood with cross-linked PVP to remove residual iodine therein.
Preferably the cross-linked PVP-iodine has a particle size of about 40-150 microns.
The active agent for removing pathogenic microorganisms present in blood is the cross-linked complex of polyvinylpyrrolidone and iodine. This complex is formed as the reaction product of cross-linked polyvinyl¬ pyrrolidone, which is available from International Specialty Products (ISP) , and molecular iodine. The cross-linked PVP-iodine is available from ISP as a stable, free-flowing powder which is water-insoluble. The preferred cross-linked PVP-iodine product can be characterized as having about 10% available iodine and about 5% iodide in the complex. EXAMPLE
A filter having a porosity equivalent to a 325 mesh screen, i.e. a porosity of 44 microns, was loaded with cross-linked PVP-iodine powder prepared according to the method of the aforementioned U.S. Patent Application, and having a particle size greater than 44 microns, to a bed depth of about 3 inches. Then a blood composition, with any microorganisms therein, was passed through the thus-loaded filter for a contact time of about 2 minutes. The filtrate thus-obtained showed less than 25 ppm of iodine therein. This treatment is effective in killing any microorganisms, including viruses, present in the blood sample. The blood cells of the treated blood remained on the filter bed; these blood cells and the cross-linked PVP-iodine are washed with isotonic solution, and transferred to a second filter having a porosity greater than the particle size of the cross-linked PVP-iodine but smaller than the red and white blood cells. In this second filter, washing with isotonic solution will separate the cross-linked PVP-iodine from the treated red and white blood cells.
The filtrate which has dead bacterial cells and dead viruses included therein is subjected to a second filtration to remove the dead bacterial cells present therein. As a feature of the invention, the treated soluble portion of the blood is purified by contacting it with cross-linked PVP to remove any residual iodine therein. In this manner, soluble blood is obtained which is substantially free of pathogenic microorganisms and residual iodine. A preferred method for accomplishing this is to provide a purification filter loaded with cross-linked PVP, and passing the treated soluble portion of the blood through the loaded filter whereupon the PVP will complex with residual iodine therein on the filter, while the purified, treated soluble portion of the blood passes through.

Claims

WHAT IS CLAIMED IS:
1. A method of treating a blood sample to inactivate pathogenic microorganisms which may be present therein comprising contacting said blood with cross-linked PVP-iodine, separating said cross-linked PVP-iodine and the cells in the blood from the soluble portion of the blood, and purifying the treated soluble portion of the blood to remove residual iodine therein.
2. A method according to claim 1 wherein purifying is carried out by contacting it with cross-linked PVP.
3. A method according to claim 1 of treating a blood sample to inactivate pathogenic microorganisms which may be present therein comprising:
(a) loading cross-linked PVP-iodine onto a filter having a porosity less than the particle sizes of both said cross-linked PVP-iodine and the blood cells in said blood,
(b) contacting the loaded filter with said blood for a period of time sufficient to enable said cross-linked PVP-iodine to kill all of said pathogenic microorganisms present in the blood,
(c) passing the thus-treated soluble portion of the blood sample through said filter, and collecting the treated blood cells; and
(d) contacting the treated soluble portion of the blood with cross-linked PVP to remove residual iodine therein.
4. A method according to claim 3 wherein, before collection, the treated blood cells on the filter first are separated from the smaller cross-linked PVP-iodine material thereon.
5. A method according to claim 4 in which said separation is effected by transferring the mixture of said cross-linked PVP-iodine and treated blood cells to a second filter having a porosity greater than the particle size of said cross-linked PVP-iodine but smaller than the cells therein, washing the mixture thereon with isotonic solution to enable the cross-linked PVP-iodine to pass through the second filter while retaining the treated blood cells thereon.
6. A method according to claim 3 wherein said filter is at least a 325 mesh screen having a porosity of less than about 44 microns.
7. A method according to claim 5 wherein said second filter has a porosity of greater than about 44 microns.
8. A method according to claim 3 wherein the cross-linked PVP-iodine has a particle size of about 40-150 microns.
9. A method according to claim 3 wherein the treated soluble portion of the blood composition has less than 25 ppm available iodine therein, and said period of contact time is at least two minutes.
10. A method according to claim 3 wherein (d) is carried out by loading cross-linked PVP onto a filter, and passing the treated soluble portion of the blood through said loaded filter to remove residual iodine therein by complexation.
PCT/US1992/008060 1991-10-08 1992-09-21 Method of treating blood WO1993006911A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77316691A 1991-10-08 1991-10-08
US773,166 1991-10-08
US83837692A 1992-02-19 1992-02-19
US838,376 1992-02-19

Publications (1)

Publication Number Publication Date
WO1993006911A1 true WO1993006911A1 (en) 1993-04-15

Family

ID=27118714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/008060 WO1993006911A1 (en) 1991-10-08 1992-09-21 Method of treating blood

Country Status (2)

Country Link
AU (1) AU2685892A (en)
WO (1) WO1993006911A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559856A1 (en) * 1991-09-03 1993-09-15 Edward Shanbrom Antimicrobial preservation of platelets and blood factors
EP0614368A4 (en) * 1992-05-04 1994-04-12 Edward Shanbrom Safe human transfusion blood.
EP0605690A1 (en) * 1992-06-29 1994-07-13 Edward Shanbrom Povidone hydrogen peroxide preservation of blood, tissues and biological fluids
WO1995016511A1 (en) * 1993-12-17 1995-06-22 Basf Aktiengesellschaft Deep-bed filter for exterminating micro-organisms and inactivating viruses and its use
US5591350A (en) * 1994-04-15 1997-01-07 Pall Corporation Iodine disinfection method using a gaseous iodine treated porous medium
WO1997048422A1 (en) * 1996-06-21 1997-12-24 Edward Shanbrom Iodinated gel filtration media for disinfecting protein solutions
EP0910460A1 (en) * 1996-06-21 1999-04-28 American Red Cross Iodinated matrices for disinfecting biological fluids
US6106773A (en) * 1998-09-24 2000-08-22 American National Red Cross Pathogen inactivating compositions for disinfecting biological fluids
WO2001010208A1 (en) * 1999-08-05 2001-02-15 Hemo-Biotech, Inc. Deactivation of toxic biological agents in biological fluids such as blood
WO2001030402A1 (en) * 1999-10-22 2001-05-03 Shanbrom Technologies Llc Protection of labile proteins during iodine disinfection

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE347807T1 (en) * 1992-09-16 2007-01-15 Triosyn Holding Inc METHOD FOR DISINFECTING AIR USING DISINFECTING IODINE RESIN AND SYSTEMS FOR DISINFECTING MICRO-ORGANISMS CONTAINED IN AIR

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017407A (en) * 1973-05-14 1977-04-12 West Laboratories, Inc. Methods for preparing solid iodine carrier mixtures and solid formulations of iodine with iodine carriers
US4312833A (en) * 1974-11-14 1982-01-26 Smith & Nephew Pharmaceuticals, Ltd. Sterilizing hydrophilic contact lenses
US4321257A (en) * 1974-07-08 1982-03-23 Johnson & Johnson Potentiated medicaments
US4997625A (en) * 1985-08-07 1991-03-05 Simon Gilbert I Chemical sterilization
US5071648A (en) * 1989-04-06 1991-12-10 Merocel Corporation Polymeric broad-spectrum antimicrobial materials
US5126127A (en) * 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017407A (en) * 1973-05-14 1977-04-12 West Laboratories, Inc. Methods for preparing solid iodine carrier mixtures and solid formulations of iodine with iodine carriers
US4321257A (en) * 1974-07-08 1982-03-23 Johnson & Johnson Potentiated medicaments
US4312833A (en) * 1974-11-14 1982-01-26 Smith & Nephew Pharmaceuticals, Ltd. Sterilizing hydrophilic contact lenses
US4997625A (en) * 1985-08-07 1991-03-05 Simon Gilbert I Chemical sterilization
US5071648A (en) * 1989-04-06 1991-12-10 Merocel Corporation Polymeric broad-spectrum antimicrobial materials
US5126127A (en) * 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559856A4 (en) * 1991-09-03 1993-11-10 Edward Shanbrom Antimicrobial preservation of platelets and blood factors
EP0559856A1 (en) * 1991-09-03 1993-09-15 Edward Shanbrom Antimicrobial preservation of platelets and blood factors
EP0614368A4 (en) * 1992-05-04 1994-04-12 Edward Shanbrom Safe human transfusion blood.
EP0614368A1 (en) * 1992-05-04 1994-09-14 Edward Shanbrom Safe human transfusion blood
EP0605690A1 (en) * 1992-06-29 1994-07-13 Edward Shanbrom Povidone hydrogen peroxide preservation of blood, tissues and biological fluids
EP0605690A4 (en) * 1992-06-29 1994-12-07 Edward Shanbrom Povidone hydrogen peroxide preservation of blood, tissues and biological fluids.
US6083408A (en) * 1993-12-17 2000-07-04 Basf Aktiengesellschaft And Schenk Filterbau Gmbh Depth-type filter for killing microorganisms and inactivating viruses which comprises a fibrous material and crospovidone-iodine and its use
WO1995016511A1 (en) * 1993-12-17 1995-06-22 Basf Aktiengesellschaft Deep-bed filter for exterminating micro-organisms and inactivating viruses and its use
US5591350A (en) * 1994-04-15 1997-01-07 Pall Corporation Iodine disinfection method using a gaseous iodine treated porous medium
US6096216A (en) * 1994-06-09 2000-08-01 American National Red Cross Iodinated matrices for disinfecting biological fluids
EP0910460A4 (en) * 1996-06-21 1999-09-15 American Nat Red Cross Iodinated matrices for disinfecting biological fluids
EP0910460A1 (en) * 1996-06-21 1999-04-28 American Red Cross Iodinated matrices for disinfecting biological fluids
WO1997048422A1 (en) * 1996-06-21 1997-12-24 Edward Shanbrom Iodinated gel filtration media for disinfecting protein solutions
US6106773A (en) * 1998-09-24 2000-08-22 American National Red Cross Pathogen inactivating compositions for disinfecting biological fluids
WO2001010208A1 (en) * 1999-08-05 2001-02-15 Hemo-Biotech, Inc. Deactivation of toxic biological agents in biological fluids such as blood
WO2001030402A1 (en) * 1999-10-22 2001-05-03 Shanbrom Technologies Llc Protection of labile proteins during iodine disinfection
AU778464B2 (en) * 1999-10-22 2004-12-09 Shanbrom Technologies, Llc Protection of labile proteins during iodine disinfection

Also Published As

Publication number Publication date
AU2685892A (en) 1993-05-03

Similar Documents

Publication Publication Date Title
WO1993006911A1 (en) Method of treating blood
US6106773A (en) Pathogen inactivating compositions for disinfecting biological fluids
AU721799B2 (en) Iodinated matrices for disinfecting biological fluids
US5370869A (en) Antimicrobial preservation of platelets and blood factors
CA2264345A1 (en) Septicemia prevention and treatment system
US7517537B1 (en) Process for decontaminating a fluid
JPH09510650A (en) Deep bed filter and its use for killing microorganisms and inactivating viruses
EP1044696A2 (en) Removal of enveloped viruses from blood, plasma or serum
US5591350A (en) Iodine disinfection method using a gaseous iodine treated porous medium
EP1037923B2 (en) Method for preparing by filtration a virally secure factor viii solution
WO1995019998A1 (en) Oxidizing resin for iodide conversion and retention
JP5080713B2 (en) Method for producing virus-removed plasma protein composition by porous membrane treatment, virus-removed plasma protein composition, and virus removal method
JP2914666B2 (en) Purification method
EP0679405A1 (en) Method for separating viruses from protein solutions
US6045787A (en) Protection of labile proteins during iodine disinfection
JP4646114B2 (en) Plasma preparation or serum preparation and method for producing the same
AU648823B2 (en) Antimicrobial preservation of plasma
WO1999041274A1 (en) A method for the removal of causative agent(s) of transmissible spongiform encephalopathies from protein solutions
JPH06511013A (en) Albumin-Iodine Preservation of Blood, Tissues and Biofluids
JP2002505674A (en) Method for removing viruses and molecular pathogens in biological material
WO1993004731A1 (en) Iodine-iodide treatment of red blood cells
CA2387859C (en) Protection of labile proteins during iodine disinfection
JPH06511016A (en) safe biofluids
JPH0751064A (en) Liquid papain and its production
JPH10130623A (en) Metal ion scavenger and method for cleaning soil

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA